Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01691079 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes
A Phase 4 study of Bronchospasm, Exercise-Induced, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01691079 is a Phase 4 study of Bronchospasm, Exercise-Induced that has completed, run by University of California, San Francisco. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01691079, a Phase 4 study of Bronchospasm, Exercise-Induced, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a double-blind placebo-controlled study in which we plan to study 40 competitive endurance athletes. We will conduct an exercise test to evaluate maximal oxygen uptake and 2 exercise challenge tests to provoke EIA. Prior to the exercise challenge tests the athletes will randomly receive inhaled placebo or inhaled ipratropium bromide. We will compare the athletes' airway response to the exercise challenge with and without the active drug.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ipratropium bromide
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01691079
The ClinicalTrials.gov registry entry for NCT01691079 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bronchospasm, Exercise-Induced appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01691079 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01691079 about?
NCT01691079 is a clinical study titled "Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes". This will be a double-blind placebo-controlled study in which we plan to study 40 competitive endurance athletes. We will conduct an exercise test to evaluate maximal oxygen uptake and 2 exercise challenge tests to provoke EIA. Prior to the exercise challenge tests the athletes will randomly receive...
What is the current status of trial NCT01691079?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2012-12. Estimated completion is 2014-12.
What conditions does trial NCT01691079 study?
This clinical trial studies the following conditions: Bronchospasm, Exercise-Induced.
What interventions are being tested in trial NCT01691079?
The interventions under investigation include: Placebo (DRUG), ipratropium bromide (DRUG).
Who is sponsoring clinical trial NCT01691079?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01691079 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.